Free tool
FAERS Monitor: Multaq
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022425 or its brand name (Multaq, Dronedarone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
10,242
Serious
7,225
71% of reports
Hospitalization
3,376
Death reported
673
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- atrial fibrillation1,428
- dyspnoea850
- fatigue627
- off label use571
- diarrhoea487
- nausea479
- drug interaction471
- dizziness454
- gastrointestinal haemorrhage421
- asthenia385
- drug ineffective337
- blood creatinine increased311
- headache241
- malaise224
- cardiac failure223
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 200 |
| 2010 | 1,088 |
| 2011 | 1,499 |
| 2012 | 632 |
| 2013 | 789 |
| 2014 | 747 |
| 2015 | 787 |
| 2016 | 645 |
| 2017 | 483 |
| 2018 | 471 |
| 2019 | 501 |
| 2020 | 405 |
| 2021 | 318 |
| 2022 | 302 |
| 2023 | 294 |
| 2024 | 327 |
| 2025 | 413 |
| 2026 | 341 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,917 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| atrial fibrillationSignal | 1,428 | 30.5 | 29.1 | 40,368 |
| gastrointestinal haemorrhageSignal | 421 | 10.4 | 9.5 | 3,560 |
| blood creatinine increasedSignal | 311 | 9.8 | 8.8 | 2,452 |
| drug interactionSignal | 471 | 6.1 | 5.6 | 2,018 |
| cardiac failureSignal | 223 | 5.7 | 5.0 | 864 |
| dyspnoeaSignal | 850 | 3.1 | 2.9 | 1,228 |
| astheniaSignal | 385 | 2.1 | 1.9 | 226 |
| dizziness | 454 | 1.9 | 1.7 | 187 |
| fatigue | 627 | 1.7 | 1.5 | 168 |
| diarrhoea | 487 | 1.5 | 1.4 | 97 |
| off label use | 571 | 1.3 | 1.2 | 51 |
| nausea | 479 | 1.2 | 1.1 | 23 |
| malaise | 224 | 1.0 | 0.9 | 0 |
| headache | 241 | 0.8 | 0.7 | 14 |
| drug ineffective | 337 | 0.5 | 0.5 | 154 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.